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Abstract
To determine signaling pathways responsible for mod-
ulation of COX-2 expression in nontransformed and
transformed epithelial cells, we studied a rat intestinal
epithelial (RIE) cell line expressing constitutively ac-
tive Ras and RhoA. Expression of COX-2 protein was
higher in RIE-RhoA(63L) (four-fold) and RIE-Ras(12V)
(seven-fold) cells than in parental cells. Prior work
suggests that Ras hyperactivity induces the expres-
sion of transforming growth factor (TGF) B and in-
creases epidermal growth factor (EGF)–related peptide
signaling—possible mechanisms for increased COX-2
expression. Expression of COX-2 was stimulated by
TGFB and TGFA in RIE and RIE-Rho(63L) cells, but
not further stimulated in RIE-Ras(12V) cells. PD153035,
an inhibitor of EGF receptor tyrosine kinase, and
PD98059, an inhibitor of Erk, attenuated COX-2 expres-
sion in RIE and RIE-RhoA(63L). However, the high
levels of COX-2 expression in RIE-Ras(12V) cells were
not inhibited by either compound. Titration with a pan-
neutralizing anti-TGFB antibody did not decrease COX-2
in RIE-Ras(12V) cells, even with concurrent EGFR in-
hibition. Thus, stimulation of the EGF receptor is im-
portant in the modulation of COX-2 expression in
nontransformed RIE and RIE-RhoA(63L) cells. In Ras-
transformed cells, signaling by additional Ras effec-
tor pathways, perhaps the RhoA pathway, must be
invoked. Identification of these pathways is critical for
therapeutic manipulation of COX-2 expression.
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Introduction
Cyclooxygenases (COXs), or prostaglandin–endoperoxide
synthetases, catalyze the rate-limiting step in the synthesis
of prostaglandins and other eicosanoids from arachidonic
acid [1]. COX-1 and COX-2 are recognized as constitutive
and inducible COX isoenzymes, respectively. Increased
expression of COX-2 and prostaglandins has been widely
observed in human [2] and rodent intestinal tumors [3,4] when
compared with normal adjacent mucosa, whereas COX-1
expression is not differentially expressed. Among the conse-
quences of elevated COX-2 expression and increased prosta-
glandin production are stimulation of angiogenesis, inhibition of
apoptosis, and stimulation of cellular proliferation, all of which
favor tumorigenesis. Inhibitors of COX-2 activity such as aspi-
rin, nonsteroidal anti-inflammatory agents (NSAIDs), and spe-
cific COX-2 antagonists significantly reduce the occurrence
of colorectal carcinoma in both animal and human studies
(reviewed in Ref. [5]). In addition, experimental animal and
human data show that individuals with colon adenomas occur-
ring in the context of a defect in the adenomatous polyposis coli
(APC) gene product show a significant reduction in the number
of adenomas following treatment with NSAIDs or more specific
COX-2 inhibitors [6,7]. Collectively, these observations indi-
cate that understanding the regulation of COX-2 activity is
linked to unraveling the pathogenesis of colorectal cancer and
to identifying strategies for its treatment and prevention.
In cell culture systems, a wide variety of growth factors and
cytokines induce COX-2 expression, including epidermal
growth factor (EGF)–related peptides [8], keratinocyte growth
factor [9], basic fibroblast growth factors [10], transforming
growth factor b (TGFb) [11], hepatocyte growth factor [12],
platelet-derived growth factor [13], interferon g [14], and gastrin
[15], among many others. Inasmuch as many of these growth
factors are overexpressed in colorectal polyps and cancers,
it is perhaps not unexpected that these same tumors fre-
quently demonstrate markedly elevated levels of COX-2 and
prostaglandins. Many growth factors stimulate cell surface
membrane–associated tyrosine kinase receptors that activate
cellular Ras and its associated effector pathways. Activating
mutations in the K-ras protooncogene are found in approxi-
mately 50% of colorectal cancers, and multiple cell culture
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studies have reported the overexpression of COX-2 in the
context of the mutant activation of Ras [16–18]. In some
cell culture models, this induction appears to occur through
increased COX-2 transcription [16] and an increase in the
half-life of the COX-2 mRNA by activation of protein kinase
B1 [19]. In addition to the activation of Ras, activation of
other small GTPases such as RhoA may also increase
COX-2 transcription by a Ras-independent pathway [17,20].
Clarification of the signaling pathways by which onco-
genic Ras upregulates COX-2 may be important in under-
standing the pathogenesis of aberrant growth-regulatory
pathways in the intestine. In its activated, GTP-bound state,
Ras stimulates a complex network of downstream pathways
potentially involved in COX-2 upregulation [21], including
stimulation of EGF-related peptide synthesis, activation of
EGFRs [22], and activation of TGFb transcription [23]. Acti-
vation of EGF signaling by Ras is especially interesting in
light of recent studies highlighting synergy between the
inhibition of COX-2 activity and the blockade of the EGFR
signaling in models of colorectal neoplasia [24].
Herein, we examine the differential regulation of COX-2
expression in transformed and nontransformed intestinal
epithelial cell model systems. Emphasis is given to the impor-
tance of epidermal growth factor receptor (EGFR) intrinsic
tyrosine kinase activity and TGFb signaling in the regulation
of COX-2 expression by Ras and Rho GTPases pathways
in RIE-1 intestinal epithelial cells.
Materials and Methods
Cell Lines and Reagents
RIE-1 rat intestinal epithelial cells were obtained from Ken
Brown (Cambridge, UK) and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
5% fetal calf serum [25]. Dr. Robert Coffey (Vanderbilt Uni-
versity) kindly supplied RIE-Ras(12V) and RIE-Rho cells,
which have been described in more detail elsewhere [26].
Briefly, RIE-Ras(12V) cells were stably transfected with
pSV2-H-ras(12V) containing human sequences encoding the
transforming H-Ras(12V) protein. RIE-RhoA(63L) cells were
established by stable transfection with mutant active RhoA(63L)
(pZIP-RhoA-63L). Unless otherwise noted, the cells used in
our studies were propagated from pools of multiple G418-
resistant clones (> 50). Ras hyperactivity in the RIE-Ras(12V)
cells was confirmed based on binding of GTP-Ras to immo-
bilized Raf-1, as previously reported by our laboratory [27].
In selected experiments, double stable transfectants were
used. For these studies, RIE-Ras(12V) cells were trans-
fected with dominant-negative mutant RhoA(N19) (kindly
supplied by Dr. Gary Bokoch). RhoA(N19) was subcloned
into pcDNA3.1/Zeo and transfected into RIE-Ras(12V)
cells using the Lipofectamine 2000 protocol supplied by
Invitrogen Life Technologies (Carlsbad, CA). Stable clones
were double-selected in Zeocin and G418. Expression of
RhoA(N19) was verified by Western blot analysis using both
anti-HA and anti-RhoA antibodies. Multiple clones were
selected for testing.
EGF was obtained from Calbiochem-Novabiochem Corp.
(San Diego, CA). TGFb1 was obtained from R&D Systems
(Minneapolis, MN). The following signaling inhibitors were
obtained from Calbiochem-Novabiochem Corp.: PD153035
(EGFR tyrosine kinase inhibitor), PD98059 (MEK inhibitor),
and Y-27632 (p160ROCK inhibitor). U0126 was obtained
from Promega Corporation (Madison, WI). EKI-785 was a
kind gift from Dr. Robert Coffey. A rabbit polyclonal anti–
human COX-1 antibody and a goat polyclonal anti–human
COX-2 antibody were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). A mouse monoclonal anti–cyclin
D1 antibody was obtained from Santa Cruz Biotechnology.
Cell Proliferation Assays
3H thymidine incorporation assays were carried out in
24-well tissue culture plates as described previously [28].
Cells were seeded at a density of 20,000 cells/well, allowed
to attach for at least 24 hours, then treated as described in
the figure legend. A 3H thymidine (Amersham Life Sciences,
Arlington Heights, IL) pulse (1 mCi/well) was provided be-
tween the 18th and 21st hours of treatment. Radioactivity in-
corporated into trichloroacetic acid–insoluble material was
determined by scintillation counting and results are presented
as the mean ± SEM for triplicate or quadruplicate measure-
ments. Experiments were repeated at least three times.
Immunoprecipitation and Western Blot Analysis
Cells in 12-well plates or 100-mm culture dishes were
solubilized in lysis buffer (20 mM Tris–HCl, pH 7.4, 120 mM
NaCl, 100 mM NaF, 200 mM Na3VO4, 4 mM PMSF, 10 mg/ml
leupeptin, 10 mg/ml aprotinin, 0.5% NP-40, and 2 mM ben-
zamidine) for 30 minutes at 4jC. The lysate was clarified by
centrifugation and the supernatant was incubated with pri-
mary antibody overnight at 4jC. Immunoprecipitates were
incubated with protein A-agarose for 1.5 hours and washed
repeatedly in phosphate-buffered saline containing 0.05%
NP-40. The immune complexes were eluted in SDS sample
buffer and transferred onto PVDFmembranes in 25 mM Tris,
192 mM glycine, and 20% methanol buffer at 30 V overnight.
Membranes were then blocked, probed with the diluted
antibody of interest, and then incubated with horseradish
peroxidase–conjugated anti-IgG. The ECL Plus detection sys-
tem (Amersham Life Sciences) was used to detect antigen–
antibody complexes.
Prostaglandin E2 (PGE2) Assay
Cells were plated in 24-well plates and grown in serum-
containing medium for 24 to 28 hours. The medium was
replaced with serum-free DMEM for 24 hours, which was
then collected for measurements of basal levels of secreted
PGE2 by enzyme-linked immunoabsorbent assay (ELISA;
Cayman Chemical, Ann Arbor, MI).
Northern Analysis
Total cellular RNA was extracted using Trizol. RNA sam-
ples (20 mg/lane) were loaded into 1% agarose/formaldehyde
gels and separated by electrophoresis and blotted onto
nitrocellulose membranes. COX-1 and COX-2 cDNA probes
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were labeled by random primer extension using Redivue with
a-32P dCTP and the Rediprime DNA labeling system from
Amersham Life Sciences. After hybrizidation and washing,
the membranes were subjected to autoradiography. The
integrity of the RNA was assessed by 18 rRNA signals.
Results
Expression and Activity of COXs in RIE, RIE-Ras(12V),
and RIE-Rho(63L) Cells
COX-2 expression is increased in cells transformed by on-
cogenic activation of Ras [16,17,29,30]. Induction of COX-2
by RhoA activation has recently been reported, but is less
well studied [17]. As previously shown, COX-2 expression in
RIE-1 cells stably transfected and transformed with activated
Ras showed a marked increase by immunoblot analysis
(Figure 1). The level of COX-2 expression was also examined
in cells that overexpress mutant-activated RhoA. These cells,
which are nontransformed, exhibit four-fold greater COX-2
expression than parental RIE-1 cells, but less than that ob-
served for transformed RIE-Ras(12V) cells. Expression of
COX-1, a constitutive COX, is equivalent in these three cell
lines. To supplement these observations, the level of PGE2,
a product of COX activity, was measured to determine if
the level of COX-2 protein observed in the RIE-Ras(12V) and
RIE-RhoA cells lines is associated with an increase in prosta-
glandin synthesis. The level of PGE2 in RIE-Ras(12V) cells
was 70-fold greater than the parental RIE-1 cell line, whereas
levels in RIE-RhoA(63L) cells were two-fold greater. Although
PGE2 has previously shown to be the predominant prosta-
glandin synthesized in the context of Ras transformation,
similar detailed studies have not been performed in cells over-
expressing RhoA and it is plausible that other prostaglandins
are synthesized in greater abundance. Notwithstanding, these
results confirm increased expression of COX-2 protein and
activity in both RIE-Ras(12V) and RIE-RhoA(63L) cells, when
compared with the parental RIE-1 cell line.
In nontransformed cells, proliferation is regulated, in part,
by cell density and confluence, whereas in transformed cells,
contact inhibition is lost. Expression of EGF-related pep-
tides, EGFRs, and EGF-signaling proteins is also regulated
by epithelial cell density [31,32]. Therefore, we examined
the expression of COX-2 protein as a function of RIE-1, RIE-
Ras(12V), and RIE-RhoA(63L) cell confluence (Figure 2). In
the nontransformed RIE-1 and RIE-RhoA(63L) cells, expres-
sion of COX-2 was decreased by approximately 60% when
measured 48 hours after cells reached confluence. By con-
trast, the transformed RIE-Ras(12V) cells showed little dif-
ference in their high level of COX-2 expression, even at
72 hours—a time when the cells have become densely con-
fluent. Thus, the high levels of COX-2 expressed in RIE-
Ras(12V) cells occur independent of cellular confluence,
whereas contact inhibition in nontransformed cells is asso-
ciated with decreased COX-2 expression.
Regulation of COX-2 Expression by EGF-Related
Peptides and TGF
It is well established that COX-2 levels are increased
by EGF-related peptides and TGFb in a variety of cell lines,
Figure 1. Expression of COX-2 protein and determination of PGE2 levels in intestinal epithelial cell lines. Total cellular lysates from RIE-1, RIE-Ras(12V), and RIE-
RhoA(63L) cells growing in subconfluent cultures were isolated, and the basal expression of COX-2 and COX-1 was examined by Western blot analysis. The bar
graph shows the relative expression of COX-2 in each cell line determined by densitometry. The graph on the right shows PGE2 levels in serum-free cell culture
medium collected from each cell line. PGE2 levels were measured by ELISA as described in the Materials and Methods section.
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including the RIE-1 line used herein. To investigate the
relative induction of COX-2 in RIE-1 cells overexpressing
activated Ras(12V) and RhoA(63L), we compared the in-
duction of COX-2 in response to treatment with TGFa and
TGFb. Consistent with prior reports [8], COX-2 was rapidly
and markedly induced in RIE cells following treatment
with TGFa, approximately 13-fold after 8 hours of treatment
(Figure 3). Similarly, COX-2 was induced in the nontrans-
formed RIE-RhoA(63L) cell line, albeit less than the paren-
tal cell line. The RIE-Ras(12V) cell line, which already has
a markedly increased level of COX-2, showed no further
induction in response to treatment with TGFa.
Although the level of COX-2 induction by TGFb was
less prominent than for TGFa, qualitatively, the observations
are similar [i.e., COX-2 is rapidly induced in the nontrans-
formed cell lines, but not further induced in the transformed
RIE-Ras(12V) cell line] (Figure 3). These results indicate
that increased levels of COX-2 expression characteristic of
RIE-Ras(12V) cells cannot be further induced in response
to autocrine growth-regulatory factors that are commonly
overexpressed in transformed intestinal epithelial cells. The
data suggest that overexpression of EGF-related peptides,
such as TGFa or TGFb, is possibly a major driving force
for COX-2 overexpression in RIE-Ras(12V) cells, and that
Figure 2. Regulation of COX-2 expression as a function of cell density. Cultures of RIE-1, RIE-Ras(12V), and RIE-RhoA(63L) cells were grown to the point at which
they just reached confluence. This time point was considered time 0. Continued postconfluent growth of cells was allowed to occur and, at 24-hour intervals
thereafter, cell lysates were isolated, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in a single gel, and subjected to
Western blot analysis for COX-2 expression. Because RIE-Ras(12V) cells did not show downregulation of COX-2 expression 48 hours after reaching confluence,
an additional 24 hours of postconfluence growth was permitted. Quantified results, obtained by densitometry, are shown in the bar graph.
Figure 3. Induction of COX-2 protein expression by TGFa and TGF. Rapidly growing cultures of RIE-1, RIE-Ras(12V), and RIE-RhoA(63L) cells were treated with
2 ng/ml TGFa or 2 ng/ml TGF1 for the indicated time period. Total cellular lysates were collected, and COX-2 protein expression was examined by Western
analysis using a COX-2–specific antibody. These experiments were performed three separate times and representative results are shown. As shown in Figures 1
and 2, the relative level of COX-2 expression is different for each cell line. In this figure, autoradiographic exposures for each cell line were varied to optimize
exposure levels and results were quantified by densitometry.
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addition of these peptides does not further increase the
expression of COX-2.
Characterization of EGFR Tyrosine Kinase Inhibition
in the RIE-Ras(12V) Cell Line
In our studies, the RIE-1 intestinal epithelial cell line is
utilized as a model for normal intestinal epithelial cells,
whereas RIE-Ras(12V) cells are used as a model for trans-
formed cells. Prior studies have shown that parental RIE-1
cells are morphologically nontransformed and do not form
colonies in soft agar, nor do they form tumors in nude mice
[26]. In contrast, RIE cells that overexpress mutant-activated
Ras(12V) assume a transformed morphology, form colonies
in soft agar, and rapidly form tumors in nude mice [26].
These characteristics have been attributed, in part, to
production of EGF-related peptides. To determine the effect
of EGFR kinase inhibition on the growth and morphology of
RIE-Ras(12V) cells, PD153035 (AG1517) was used in 3H
thymidine incorporation assays. As shown in Figure 4, DNA
synthesis was decreased by concentrations of the tyro-
sine kinase inhibitor between 0.05 and 2 mM, whereas 2 mM
AG9, an inactive tyrphostin analogue, had no significant
effect. Similar results were observed with the tyrosine
kinase inhibitor, tyrphostin (AG1478). No effect was ob-
served on the morphology of cells. Based on the near
equivalence of tyrphostin and PD153035, further experi-
ments described in this manuscript were performed using
the latter compound. The inset in Figure 4 shows a marked
decreased in the tyrosine phosphorylation of EGFR in RIE-
Ras(12V) cells at a PD153035 concentration of 1 mM.
Collectively, these concentrations are consistent with ef-
fective tyrosine kinase inhibitor concentrations reported
Figure 4. EGFR tyrosine kinase inhibitors decrease 3H thymidine incorporation but not COX-2 levels in Ras-transformed cells. RIE-Ras(12V) cells were rapidly
treated with the indicated concentration of the tyrosine kinase inhibitor, PD153035, in serum-free medium. Eighteen hours later, a 3-hour pulse of 3H thymidine
(1 Ci/well) was provided, followed by measurements of thymidine incorporation into TCA-insoluble materials, as described in the Materials and Methods section.
AG9, an inactive structural analogue of AG1478, was used as a control in these experiments, and identical experiments with AG1478 were performed (not shown).
Results, shown in the top panel, are expressed as percent of 3H thymidine incorporation in cells treated with dimethyl sulfoxide alone. Rapidly growing cultures of
RIE-1, RIE-Ras(12V), and RIE-RhoA(63L) cells were treated for 24 hours with the highly specific tyrosine kinase inhibitor, PD153035, at concentrations between
0.01 and 25 mg/ml. Note that the inhibitor concentrations varied for each cell line. Total cellular lysates were collected and COX-2 protein expression was examined
by Western blot analysis using a COX-2–specific antibody. These experiments were performed three separate times and representative results are shown. As
shown in Figures 1 and 2, the relative level of COX-2 expression is different for each cell line. In this figure, autoradiographic exposures for each cell line were
varied to optimize exposure levels. Because of the apparent insensitivity of RIE-Ras(12V) cells to PD153035, its activity as a tyrosine kinase inhibitor was checked
in separate experiments, under identical conditions, using an alternate EGFR tyrosine kinase inhibitor, EKI-758. Again, reduced levels of COX-2 are not observed
(bottom right). The inset shows that at a concentration of 1 g/ml, PD153035 markedly inhibited EGFR phosphorylation, but not COX-2 expression, as shown by
the arrow. In the experiment shown in the right panel, cells were grown to near confluence and treated with a pan-neutralizing anti-TGF antibody for 24 hours.
COX-2 protein expression in each cell line was measured by Western blot analysis.
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previously [33–35], and substantiate the design of subse-
quent experiments on COX-2 expression reported herein.
The results also show the critical dependence of increased
EGFR tyrosine kinase activity on cellular proliferation in RIE-
Ras(12V) cells.
Effect of EGFR Tyrosine Kinase Inhibition and TGF
Inhibition on COX-2 Expression
To test the hypothesis that COX-2 overexpression in
RIE-Ras(12V) cells is due to the high level of expression of
EGF-related peptides characteristic of these cells, RIE-1,
RIE-Ras(12V), and RIE-RhoA(63L) cells were treated for
24 hours with PD153035 at concentrations known to de-
crease the phosphorylation of EGFR (Refs. [33–35]; Figure 4,
inset ) and inhibit DNA synthesis RIE-Ras(12V) cell lines
(Figure 4, top panel ). The results show that COX-2 expres-
sion in parental RIE-1 cells is highly sensitive to the EGFR
tyrosine kinase inhibitor, with half-maximal inhibition occur-
ring between 0.02 and 0.05 mM PD153035 (Figure 4). RIE-
Rho cells are somewhat less sensitive, with a half-maximal
inhibition between 0.05 and 0.5 mM. By contrast, COX-2
levels are resistant to EGFR tyrosine kinase inhibition up to
5 mM in transformed cells overexpressing mutant-activated
Ras. This relative (100-fold) resistance in RIE-Ras(12V)
cells was confirmed by treatment with EKI-758, a structurally
distinct EGFR tyrosine kinase inhibitor (Figure 4, bottom
panel ). Collectively, these results indicate that the basal
levels of COX-2 in RIE-1– and RIE-RhoA(63L)–expressing
cells are maintained, in part, by autocrine stimulation of the
EGFR tyrosine kinase activity. Despite the high levels of
production of EGF-related peptides in RIE cells that stably
overexpress activated Ras, stimulation of the EGFR by
these autocrine growth factors is not independently respon-
sible for the maintenance of high levels of COX-2 expression
characteristic of this cell line.
COX-2 expression is also stimulated by TGFb in many cell
types, potentially explaining the increased COX-2 expres-
sion observed in Ras-transformed cells, as Ras activates
the transcription of the TGFb gene [23]. To confirm this in
RIE cells, TGFb levels in 72-hour conditioned medium were
determined by ELISA and were approximately increased
10-fold in RIE-Ras(12V) cells compared with the parental RIE
cell line (RIE = 21.1 pg/ml per 104 cells versus Ras(12V) =
191.9 pg/ml per 104 cells; RIE-RhoA(63L) cells = not per-
formed). A pan-neutralizing anti-TGFb antibody that recog-
nizes all three isoforms of mammalian TGFb was added to
the cell culture medium in each of the three cell lines under
study in an attempt to interrupt autocrine TGFb-stimulated
COX-2 expression. Addition of the pan-neutralizing antibody
(1 mg/ml) for 24 hours did not diminish COX-2 expression in
any of the cell lines (Figure 4), although this was sufficient to
reduce basal levels of Smad2 phosphorylation (not shown).
Simultaneous treatment of RIE-Ras(12V) cells with pan-
neutralizing anti-TGFb antibody and PD153035 also did
not reduce COX-2 expression. This result indicates that
autocrine production of TGFb does not contribute to the
basal levels of COX-2 expression in nontransformed or
transformed cell lines.
Figure 5. Effect of Erk pathway inhibition on COX-2 expression. Rapidly growing, subconfluent RIE-1, RIE-Ras(12V), RIE-RhoA(63L), and RIE-Ras(12V)/
RhoA(N19) cells were treated for 24 hours with the indicated concentration of the EGFR tyrosine kinase inhibitor, PD153035, and the MEK inhibitor, PD98059 (left
panel), or with U0126, a more potent inhibitor of MEK (right panel). Total cellular lysates were isolated from each cell line and loaded onto SDS-PAGE gels.
Western blot analysis was performed for COX-2 and cyclin D1 expression. This experiment was repeated three times with similar results.
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Effect of MEK and p160ROCK Inhibition on
COX-2 Expression
Activation of Ras stimulates a variety of diverse intracel-
lular signaling pathways, the most extensively studied of
which is the canonic Raf/MEK/Erk pathway. Inhibitors of
MEK were used to determine the involvement of this path-
way in the stimulation of COX-2 expression in intestinal
epithelial cell lines. Preliminary experiments (not shown)
confirmed that 25 mM PD98059 significantly inhibited MEK
activity in the cells used in this study, consistent with pub-
lished reports. Similarly, PD98059 inhibited basal COX-2
expression in parental RIE-1 cells, as well as inhibited the
intermediate level of COX-2 expression in cells expressing
activated RhoA (Figure 5). However, inhibition of COX-2 by
PD98059 did not occur in cells overexpressing activated
Ras. This observation was further explored by using U0126,
an alternate, more potent, and selective inhibitor of MEK
activity [36]. Using U0126 at a concentration of 10 mM,
inhibition of MEK was virtually complete as shown in the
inset in Figure 5, but inhibition of COX-2 expression was
modest and did not decrease to the lower level of expres-
sion observed in parental RIE or RIE-RhoA(63L) cells. Thus,
despite the expression of oncogenic Ras at a level suffi-
cient to cause transformation, activation of Erk was not fully
and independently responsible for the maintenance of high
levels of COX-2 expression characteristic of this cell line.
As shown in Figure 5, transfection of RIE-Ras(12V) cells
with a dominant-negative RhoA(N19) construct markedly
decreased COX-2 levels, as we have reported previously
[37]. The selectively of dominant-negative Rho(A) on ex-
pression was apparent by the lack of reduced cyclin D1 in
dually transfected cells. When the dual transfectant was
treated with U0126, decreased MEK activity further reduced
COX-2 expression, suggesting that Rho and MEK jointly
regulate COX-2 expression.
We previously found that activated RhoA and activated
Raf function cooperatively to transform intestinal epithelial
cells and promote the acquisition of growth characteristics
highly reminiscent of Ras-transformed cells [37]. Additionally,
we found that dominant-negative expression of RhoA in RIE-
Ras(12V) cells markedly inhibits elevated COX-2 expression
and increased PGE2 levels characteristic of cells expressing
hyperactive Ras, but did not affect levels of other proteins
relevant to cellular proliferation, such as cyclin D1 [37]. To de-
termine if the p160ROCK Rho effector pathway is involved
in the stimulation of COX-2 expression, we treated RIE-1,
RIE-Ras(12V), and RIE-RhoA(63L) cells with an inhibitor of
p160ROCK, a downstream effector Rho-kinase. Although
10 mM Y-27632 reduced basal COX-2 expression in RIE
cells by approximately 70%, significant inhibition in RIE-
RhoA(63L) and RIE-Ras(12V) cells was not observed, and
no alterations in the expression of cyclin D1 were observed,
as shown in Figure 6. These results suggest that other RhoA
effector pathways, independent of p160ROCK, are involved
in the regulation of COX-2 expression in Ras-transformed
intestinal epithelial cells.
Discussion
COX-2 is believed to play an important role in the progres-
sion of colorectal cancer. Its expression is markedly induced
in human colorectal tumors and is not detectable in adjacent
normal mucosa [2,38]. Although increased COX-2 expres-
sion is not sufficient for neoplastic transformation of cultured
intestinal epithelial cells [39], reduction of COX-2 activity in
cell culture models, experimental animals, and human re-
search subjects decreases transformed cell behavior and
tumor growth. For example, the growth of subcutaneously
implanted lung carcinoma tumor cells in COX-2/ mice is
attenuated [40] when compared with COX-2–expressing
littermates. The growth of small intestinal tumors is signifi-
cantly diminished in COX-2/ mice that are also deficient
in the APC tumor suppressor gene product [41]. Similarly,
the use of the COX-2 inhibitor, celocoxib, in persons with
FAP diminishes the number of existing adenomas by about
25% [6], although standard doses of sulindac do not prevent
the development of adenomas [42]. Thus, there is a connec-
tion between COX-2 activity and transformed cell behavior,
which is explained, in part at least, by the effect of COX-2–
derived prostaglandins on cellular proliferation, inhibition of
apoptosis, increased invasiveness, and stimulation of angio-
genesis. Thus, understanding how COX-2 levels are regu-
lated and how its activity can be modified to therapeutic
advantage has become a major area of investigation in the
past decade.
In quiescent G0 cells, COX-2 expression is low or not
detectable; its levels are induced by growth factors, such as
EGF-related peptides and TGFb, and are super-induced
by the protein synthesis inhibitor, cyclohexamide [8]. Thus,
COX-2 is regulated as an immediate early gene in non-
transformed intestinal epithelial cells and other nontrans-
formed cells [8]. Diverse intracellular signal transduction
pathways tightly regulate COX-2 expression in normal epi-
thelial cells by the regulation of gene transcription, mRNA
stability, and protein translation [43]. In the setting of cellular
Figure 6. Effect of Rho inhibition on COX-2 expression. Rapidly growing,
subconfluent RIE-1, RIE-Ras(12V), and RIE-RhoA(63L) cells were treated for
24 hours with the indicated concentration of Y-27632, an inhibitor of the
p160ROCK limb of the RhoA pathway. Total cellular lysates were isolated
from each cell line and loaded onto SDS-PAGE gels. Western blot analysis
was performed for COX-2 and cyclin D1 expression. This experiment was
repeated three times with similar results.
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transformation, COX-2 is constitutively overexpressed due
to the activation of diverse intracellular signaling pathways.
This is particularly true in the case of cells overexpres-
sing mutant-activated Ras. For example, Ras upregulates
COX-2 expression by activation of the transcription and sta-
bilization of COX-2 mRNA by ERK, JNK, p38, Rho, and Akt
signaling (reviewed in Ref. [43]). Activation of COX-2 ex-
pression by other small GTPases, such as RhoGTPases, also
occurs [17] in some cells by a p160ROCK– and NF-nB–
dependent mechanism, although there is a great deal of cell
type specificity in this response [20]. Notwithstanding this
growing body of information on intracellular signaling pathways
involved in the regulation of COX-2 expression, little significant
attention has been given to growth factor pathways that spe-
cifically activate COX-2 expression in Ras-transformed cells.
Because overexpression of EGF-related peptides and
TGFb contributes to the Ras-transformed phenotype [22,
44,45], in the present work, we examined the relative im-
portance of these growth factors in the regulation of COX-2
expression in the nontransformed rat intestinal epithelial cell
line RIE-1, and in RIE-1 cells transformed by stable trans-
fection of oncogenic Ras. In addition, regulation of COX-2 in
RIE cells overexpressing mutant-activated RhoA was also
examined because of emerging reports suggesting that
RhoA transcriptionally activates COX-2 expression and our
own work showing that simultaneous expression of activated
RhoA and activated Raf in RIE cells mimics many of the
characteristics of Ras-transformed cells [37].
EGFR activation by autocrine EGF-related peptides is
a potentially attractive mechanism for the upregulation of
COX-2 expression in Ras-transformed intestinal epithelial
cells because upregulation of these peptides commonly oc-
curs in a variety of Ras-transformed epithelial cell types, in-
cluding intestinal epithelial cells [22] and keratinocytes [45].
In fact, a number of characteristics of Ras-transformed cells
can be specifically attributed to signaling through by the
EGFR. For example, Ras-mediated induction of vascular
endothelial growth factor and tumor angiogenesis [46], growth
in soft agar andmorphologic transformation [22,26], and sen-
sitivity to Ras inhibition by farnesyltransferase inhibitors [44]
can be linked to the production of EGF-related peptides such
as transforming growth factor a, heparin-binding EGF-like
growth factor, and amphiregulin in RIE-1 cells. In the present
work, we investigated the potential role of EGFR activation
in contributing to the high levels of COX-2 in RIE-Ras(12V)
cells. Treatment of nontransformed RIE-1 and RIE-RhoA
cells with EGFR tyrosine kinase inhibitors reduced COX-2
expression in a dose-dependent fashion, indicating the stim-
ulation of EGFR tyrosine kinase, presumably by autocrine
production of TGFa, amphiregulin, betacellulin, andHB-EGF,
which we have previously found in RIE-1 cells [47]. However,
unlike the observations cited above, we found that COX-2
induction by stable Ras overexpression in RIE-Ras(12V)
cells cannot be solely attributed to EGFR activation, despite
a demonstrated inhibitory effect of EGFR tyrosine kinase
inhibitors on Ras-transformed cell growth and EGFR phos-
phorylation. Clearly, an additional pathway for the regulation
of COx-2 expression must be invoked.
TGFb increases COX-2 expression in RIE-1 cells. In our
studies, TGFb did not further increase the already ele-
vated levels of COX-2 expression in Ras-transformed cells.
We also found that inhibition of TGFb signaling by anti–
TGFb-neutralizing antibodies did not reduce COX-2 levels
in Ras-transformed cells. Our findings contrast with the
observations of Sheng et al. [29], who rapidly induced
Ras expression in RIE cells using an isopropyl-1-thio-b-
D-galactopyranoside (IPTG)– inducible construct. In this
system, TGFb further induced COX-2 expression and anti–
TGFb-neutralizing antibodies reduced, but did not eliminate,
IPTG-induced COX-2 expression. The divergence between
our study and the Sheng et al. study is likely due to technical
differences in the systems under study. Inducible systems
are excellent for the analysis of the immediate signaling
effects of oncogenic Ras overexpression, are but less at-
tractive for understanding cellular consequences of the
sustained overexpression of oncogenic Ras that typifies neo-
plasia. Conversely, because induction of genomic instability
by oncogenic Ras is a well-known phenomenon and, indeed,
all in vitro cell culture systems are susceptible to genomic
instability [48], it is feasible that other genetic alterations
contribute to variations in the regulation of COX-2 expres-
sion reported in various published studies, especially when
rodent cell lines are used.
Emerging data suggest the regulation of COX-2 expres-
sion by the small GTPase RhoA [17,20]. Recently, we found
that dominant-negative expression of RhoA in RIE-Ras(12V)
cells markedly and specifically inhibits elevated COX-2 ex-
pression and increases PGE2 levels characteristic of cells
expressing hyperactive Ras [37]. This suggests that RhoA
activation is necessary for increased COX-2 expression
in the presence of mutant-activated Ras. In support of this,
herein, we report that levels of COX-2 protein expression in
RIE cells that stably overexpress mutant-activated RhoA are
increased relative to parental RIE-1 cells, are but less than
RIE-Ras cells. In addition, stable expression of a dominant-
negative RhoA construct in RIE-Ras(12V) reduces COX-2
expression to relatively low levels seen in parental cells.
Further, this residual COX-2 expression is reduced by a
pharmacologic inhibitor of Erk activation, suggesting that
the canonic Ras/Raf/MEK,Erk pathway and Rho jointly reg-
ulate COX-2 activation. Identification of the specific RhoA
effector pathway(s) involved in the regulation of COX-2 ex-
pression will be problematic as more than 30 potential
effectors of Rho-GTPases have been identified and, in most
instances, downstream targets of these various Rho effec-
tors are not yet known [49]. Also not investigated in our
system is the potential role of other Rho proteins such as
RhoB, RhoC, and Rac1, which share overlapping effector
systems with RhoA [50]. Candidate effectors include mDIA,
rhotekin, rhophilin, and PRK, among others. In the current
study, because of the facile availability of a highly specific
pharmacologic inhibitor (Y-27632), we studied p160ROCK,
which has recently been identified as a RhoA effector pathway
involved in a variety of functions such as actin stress fiber
assembly [51] and tight junction formation [52]. Our findings
indicate that ROCK does not mediate the induction of COX-2
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in Ras-transformed cells. However, further support for the
involvement of the RhoA pathway in the regulation of COX-2
expression is suggested by our work, indicating that addi-
tional investigation of this complex pathway is needed to fully
understand the role of RhoA in the regulation of COX-2
expression in normal and transformed cells.
In summary, stimulation of the EGFR is an important
inducer of basal COX-2 expression in nontransformed cul-
ture intestinal epithelial cells and in cells overexpressing
activated RIE-RhoA(63L). By contrast, in cells transformed
by overexpression of mutant-activated Ras, increased EGFR
signaling and overproduction of TGFb do not account for
increased COX-2 expression. Emerging data suggest that
RhoA activation in Ras-transformed cells is a critical key
regulator of COX-2 expression, although the precise mech-
anism by which this occurs requires further investigation.
Identification of these complex pathways will be important in
the design of therapeutic strategies to manipulate COX-2
expression in the gastrointestinal tract.
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